TNF and COVID-19: Others have already shown that these therapies, particularly TNF inhibitors, reduce the ability of different COVID-19 vaccines (based on mRNA or adenoviral vector) to produce spike-specific antibodies (5–8), especially those that recognize SARS-CoV-2 variants, including B.1.617.2 (Delta) (4).